CORMORANT PHARMACEUTICALS

cormorant-pharmaceuticals-logo

Cormorant Pharmaceuticals is a privately held, biopharmaceutical company founded by Maarten de Chรขteau and Urban Paulsson. The company is based at the Karolinska Institute Science Park in Stockholm, Sweden. Based on mounting research pointing to IL-8 being an important driver of malignant tumors, HuMax-IL8 was acquired from Genmab A/S and taken into development by Cormorant. HuMax-IL8, is a fully human monoclonal antibody

#SimilarOrganizations #More

CORMORANT PHARMACEUTICALS

Social Links:

Industry:
Biotechnology Pharmaceutical

Founded:
2010-01-01

Address:
Solna, Stockholms Lan, Sweden

Country:
Sweden

Total Employee:
1+

Status:
Active


Similar Organizations

erimos-pharmaceuticals-logo

Erimos Pharmaceuticals

Erimos Pharmaceuticals is a biopharmaceutical company

learmont-pharmaceuticals-logo

Learmont Pharmaceuticals

Learmont Pharmaceuticals is a pharmaceutical company.

tzana-pharmaceuticals-logo

Tzana Pharmaceuticals

Tzana Pharmaceuticals is a pharmaceutical company.

More informations about "Cormorant Pharmaceuticals"

Cormorant Pharmaceuticals - Crunchbase Company Profile

Cormorant Pharmaceuticals is a privately held, biopharmaceutical company founded by Maarten de Château and Urban Paulsson. The company is based at the Karolinska Institute Science Park in Stockholm, Sweden. Based on mounting research pointing to IL-8 being an important driver โ€ฆSee details»

BMS Buys Rare Disease Biotech for Up to $500M

Jul 11, 2016 Bristol-Myers Squibb (BMS) acquired Swedenโ€™s Cormorant Pharmaceuticals, a biotech specializing in drugs for rare diseases, on July 5 in a deal that could be worth up to $500 million. The agreement gives BMS total โ€ฆSee details»

Cormorant Pharmaceuticals - LinkedIn

Cormorant Pharmaceuticals is a recently founded biopharmaceutical company focusing on the development of therapeutics for the treatment of cancer and rare diseases. Cormorant Pharmaceuticals ...See details»

Bristol-Myers Squibb buys cancer, rare disease biotech Cormorant

Jul 5, 2016 The rights to the drug originally came from a deal Cormorant struck with Copenhagen-based Genmab back in 2012, who itself bought the drug from Medarex in 2007- โ€ฆSee details»

Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals

Jul 5, 2016 Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock of โ€ฆSee details»

Cormorant Pharmaceuticals - PitchBook

Cormorant Pharmaceuticals General Information Description. Provider of pharmaceutical services. The company primarily focuses on developing therapeutics and related services for cancer and other rare diseases.See details»

Bristol-Myers Squibb Buys Privately Held Cormorant Pharmaceuticals

Jul 5, 2016 Bristol-Myers Squibb Company (NYSE: BMY ) and Cormorant Pharmaceuticals revealed Tuesday that the former has acquired privately held Cormorant Pharmaceuticals' all โ€ฆSee details»

Bristol-Myers Squibb acquires Cormorant โ€ฆ

Jul 5, 2016 Cormorant Pharmaceuticals is a private, Sweden-based pharmaceutical company focused on the development of therapies for cancer and rare diseases. The acquisition gives Bristol-Myers Squibb full rights to โ€ฆSee details»

BMS Buys Cormorant Pharmaceuticals for Up to $520M

Jul 6, 2016 Bristol-Myers Squibb (BMS) has acquired Cormorant Pharmaceuticals, a Sweden-based developer of cancer and rare-disease therapies, for up to $520 million, in a deal โ€ฆSee details»

Bristol-Myers Squibb acquires Cormorant Pharmaceuticals

Jul 5, 2016 About Cormorant Cormorant Pharmaceuticals is a privately held, biopharmaceutical company founded by Maarten de Château and Urban Paulsson. The company is based at the โ€ฆSee details»

Cormorant Pharmaceuticals - Products, Competitors, Financials ...

It recently acquired Cormorant Pharmaceuticals in an all-stock transaction with the deal worth up to $520 million to boost and strengthen its immuno-oncology pipeline. With this acquisition, it โ€ฆSee details»

Cormorant Pharmaceuticals Acquired by BMS for $520M

Jul 11, 2016 Cormorant Pharmaceuticals, developer of cancer and disease therapies, has been acquired by Bristol-Myers Squibb in a move to expand BMS pipelines. ... Cormorant acquired โ€ฆSee details»

Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals

Jul 5, 2016 Cormorant Pharmaceuticals is a privately held, biopharmaceutical company founded by Maarten de Château and Urban Paulsson. The company is based at the Karolinska โ€ฆSee details»

Cormorant Asset Management's Strategic Acquisition in Corbus ...

Sep 25, 2024 The trade not only increased Cormorant's holdings in Corbus Pharmaceuticals by 350,000 shares but also impacted the firm's portfolio by 0.4%, enhancing its position to a โ€ฆSee details»

BMS Acquires Cormorant Pharmaceuticals for Up to $520M

Jul 5, 2016 Bristol-Myers Squibb (BMS) has acquired Cormorant Pharmaceuticals, a developer of cancer and rare-disease therapies, for up to $520 million, in a deal designed to broaden the โ€ฆSee details»

Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals

Jul 5, 2016 Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant Pharmaceuticals, a private, Stockholm, Sweden-based pharmaceutical company focused on โ€ฆSee details»

Bristol-Myers buys Cormorant Pharma, eyes cancer combo potential

Jul 5, 2016 Bristol-Myers Squibb has bought Swedish firm Cormorant Pharmaceuticals in a potentially $520 million deal, adding an antibody program designed to boost the efficacy of โ€ฆSee details»

Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals

Jul 5, 2016 Bristol-Myers Squibb Companyand Cormorant Pharmaceuticals have announced that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a โ€ฆSee details»

Bristol-Myers Squibb buys rare disease biotech Cormorant โ€ฆ

Jul 6, 2016 Bristol-Myers Squibb is to buy Cormorant Pharmaceuticals in a deal which could be worth up to $520m. Under the deal, Bristol-Myers Squibb has acquired all of the outstanding โ€ฆSee details»

Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals

Bristol-Myers Squibb Company and Cormorant Pharmaceuticals announced that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a private, StockholmSee details»

linkstock.net © 2022. All rights reserved